Belgium 080040305 (Toll Free) France 0805110270 (Toll Free) Germany 08001016676 (Toll Free) Ireland 1800931389 (Toll Free) Netherlands 08009494524 (Toll Free) United Kingdom 08002799501 (Toll Free) United States (1)8666765866 (Toll Free)
for more international toll and toll free dial in numbers.
Participant pincode: 536961#
We request that participants dial in 5-10 minutes prior to the start time of
06:30 PM CET
12:30 PM EST
The presentation will be webcasted live,
The presentation and transcript of the call will be made available shortly on
under the investor relations tab.
(ocriplasmin) is a truncated form of human plasmin. In the US, JETREA
is indicated for the treatment of symptomatic VMA. In
is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter ≤ 400 microns. JETREA
is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.
has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and
involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.
's Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01).
The phase III program also showed that JETREA
was generally well tolerated. Any adverse reactions were ocular. The most commonly reported were vitreous floaters, eye pain and photopsia, as well as conjunctival haemorrhage resulting from the injection procedure. Most of the adverse reactions occurred within the first week after the injection. The majority of these reactions was non-serious, mild in intensity and resolved within 2 to 3 weeks.